Information Provided By:
Fly News Breaks for December 14, 2015
PBYI
Dec 14, 2015 | 07:07 EDT
Citi analyst Yigal Nochomovitz attributes the selloff in shares of Puma Biotechnology after the company presented the 3-year DFS follow up results from the ExteNET trial to the fact that the ITT DFS curves slightly converge, but he thinks the market is missing the fact that the HR+ subgroup look "very good," noting that those curves increased their separation at years three and four. The analyst, who sees a "high likelihood" of approval for neratinib, upgraded the stock to Buy from Neutral and put a $107 price target on the shares.
News For PBYI From the Last 2 Days
There are no results for your query PBYI